US2012219969A1PendingUtilityA1

Marker for neuromyelitis optica

55
Individually held — no corporate assignee on recordPriority: Nov 25, 2003Filed: May 14, 2012Published: Aug 30, 2012
Est. expiryNov 25, 2023(expired)· nominal 20-yr term from priority
Inventors:Vanda A. LennonThomas J. Kryzer
A61P 37/00C07K 14/705G01N 33/564A61P 25/28C07K 16/28G01N 2800/285C07K 2317/21C07K 16/18
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).

Claims

exact text as granted — not AI-modified
1 . A method of detecting the presence or absence of a neuromyelitis optica (NMO) antigenic polypeptide in a biological sample from an individual, comprising the steps of:
 contacting the biological sample with an anti-NMO antigen antibody, wherein the NMO antigen is aquaporin-4; and   detecting the presence or absence of binding of the anti-NMO antigen antibody to the biological sample, wherein the presence of binding is indicative of the presence of the NMO antigenic polypeptide in the biological sample.   
     
     
         2 . The method of  claim 1 , wherein the presence of the NMO antigenic polypeptide in the biological sample is indicative of NMO or NMO-related inflammatory disorder in said individual. 
     
     
         3 . The method of  claim 1 , wherein the individual is partially or completely blind. 
     
     
         4 . The method of  claim 1 , wherein the biological sample is selected from the group consisting of blood, serum, plasma, cerebrospinal fluid, brain biopsy and spinal cord biopsy. 
     
     
         5 . The method of  claim 1 , wherein the biological sample is a spinal cord biopsy. 
     
     
         6 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a recombinantly-generated antibody. 
     
     
         7 . The method of  claim 1 , wherein the anti-NMO antigen antibody is detectably labeled. 
     
     
         8 . The method of  claim 7 , wherein the detectable label is selected from the group consisting of a radioisotope, an enzyme, a substrate, a cofactor, an inhibitor, a fluorescer, a chemiluminescer, and a magnetic particle. 
     
     
         9 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a polyclonal antibody. 
     
     
         10 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a IgG antibody. 
     
     
         11 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a fragment of an antibody. 
     
     
         12 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a single-chain antibody molecule. 
     
     
         13 . The method of  claim 1 , wherein the anti-NMO antigen antibody is a chimeric antibody. 
     
     
         14 . The method of  claim 1 , wherein the detecting step is performed using a secondary antibody that binds to the anti-NMO antigen antibody. 
     
     
         15 . The method of  claim 1 , wherein the detecting step utilizes an immunoassay. 
     
     
         16 . The method of  claim 1 , wherein the detecting step utilizes an immunohistochemical assay. 
     
     
         17 . The method of  claim 1 , wherein the detecting step utilizes a solid phase immunoassay format. 
     
     
         18 . The method of  claim 1 , wherein the anti-NMO antigen antibody is attached to a solid surface. 
     
     
         19 . The method of  claim 1 , wherein the detecting step utilizes ELISA or Western blotting.

Join the waitlist — get patent alerts

Track US2012219969A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.